Distinct Serum Extracellular Vesicle Proteomic Profiles Characterize Hepatic Steatosis in Women After Menopause
Clinical Scorecard: Distinct Serum Extracellular Vesicle Proteomic Profiles Characterize Hepatic Steatosis in Women After Menopause
At a Glance
Category Detail
Condition Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Key Mechanisms Hormonal decline post-menopause leading to metabolic dysfunction, hepatic steatosis, and steatohepatitis. Target Population Postmenopausal women Care Setting Clinical research and community health settings
Key Highlights
MASLD prevalence in postmenopausal women increased from 18.5% to 24.9% between 1988-2014. Postmenopausal women have a nearly two-fold higher likelihood of advanced fibrosis compared to men. Extracellular vesicles (EVs) are potential biomarkers for early detection of MASLD. Routine liver assessments often fail to detect early stages of MASLD. EVs may drive disease progression and offer insights into underlying cellular functions. Guideline-Based Recommendations
Diagnosis
Utilize serum EV profiles for early detection of MASLD. Consider abdominal ultrasound for assessing hepatic steatosis. Management
Target hormonal and metabolic dysfunction in postmenopausal women. Explore therapeutic targeting of EVs in MASLD. Monitoring & Follow-up
Regular assessment of liver health in postmenopausal women. Monitor EV levels as potential indicators of disease progression. Risks
Increased risk of advanced fibrosis and liver transplantation in postmenopausal women. Potential for higher mortality rates associated with MASLD. Patient & Prescribing Data
Postmenopausal women with or at risk for MASLD.
Focus on managing metabolic dysfunction and exploring EV-targeted therapies.
Clinical Best Practices
Incorporate EV analysis into routine assessments for liver health. Educate patients on the risks of MASLD and the importance of early detection. References
